GWPH - GWファ―マシュ―ティカルズ (GW Pharmaceuticals Plc) GWファ―マシュ―ティカルズ

 GWPHのチャート


 GWPHの企業情報

symbol GWPH
会社名 GW Pharmaceuticals Plc (GWファ―マシュ―ティカルズ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols) which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial Sativex Research and Development and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.   GWファ―マシュ―ティカルズは英国のバイオ医薬品会社。色々な疾病の治療薬として、独自のカンナビノイド製品発見、開発、商業化に従事。同社の主要医薬品「サティベックス」を多発性硬化症、がんの痛み、神経痛の痛みを緩和させる口腔粘膜スプレ―治療薬として研究、開発中。   
本社所在地 Sovereign House Vision Park Chivers Way Histon Cambridge CB24 9BZ GBR
代表者氏名 Geoffrey W. Guy ジェフリーW.ガイ
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +44 1223-26-6800
設立年月日 1998年
市場名 NASDAQ National Market System
ipoyear 2013年
従業員数 583人
url www.gwpharm.com
nasdaq_url https://www.nasdaq.com/symbol/gwph
adr_tso 26599036
EBITDA EBITDA(百万ドル) -219.66910
終値(lastsale) 146.07
時価総額(marketcap) 3885321188.52
時価総額 時価総額(百万ドル) 3959.721
売上高 売上高(百万ドル) 16.56232
企業価値(EV) 企業価値(EV)(百万ドル) 3512.80622
当期純利益 当期純利益(百万ドル) -250.08300
決算概要 決算概要 BRIEF: For the six months ended 31 March 2018 GW Pharmaceuticals PLC- ADR revenues increased from £3.7M to £8.1M. Net loss increased from £50M to £109.6M. Revenues reflect Europe (Excluding UK) segment increase of 60% to £1.6M Canada segment increase from £0K to £196K. Higher net loss reflects Net foreign exchange (loss)/gain increase from £7.8M (income) to £17.2M (expense) Selling/General/Admin.

 GWPHのテクニカル分析


 GWPHのニュース

   GW Pharmaceuticals - ADR Shares Near 52-Week High - Market Mover  2021/04/30 22:30:00 Kwhen Finance
GW Pharmaceuticals - ADR (GWPH) shares closed today at 0.1% below its 52 week high of $219.18, giving the company a market cap of $6B. The stock is currently up 89.8% year-to-date, up 118.7% over the past 12 months, and up 170.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 rose 0.1%. Trading Activity Trading volume this week was 67.5% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was between 30 and 70.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 2917.7% The company's stock price performance over the past 12 months beats the peer average by -7787.3% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   GW Pharmaceuticals - ADR Shares Close in on 52-Week High - Market Mover  2021/04/23 22:30:00 Kwhen Finance
GW Pharmaceuticals - ADR shares closed today at just slightly below its 52 week high of $219.00, giving the company a market cap of $6B. The stock is currently up 89.7% year-to-date, up 108.5% over the past 12 months, and up 158.3% over the past five years. This week, the Dow Jones Industrial Average fell 0.4%, and the S&P 500 fell 0.1%. Trading Activity Trading volume this week was 9.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.5. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by 1851.3% The company's stock price performance over the past 12 months beats the peer average by 1332.9% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   The Week In Cannabis: The New Tilray, Jazz-GW Pharma, Earnings, M&A, And More  2021/05/07 21:36:03 Benzinga
This was an eventful week for the cannabis industry. On Monday, Tilray, Inc. (NASDAQ: TLRY ) and Aphria, Inc. (NASDAQ: APHA ) closed their merger after months of negotiations, creating a company with a combined market cap of $3.3 billion. Benzinga spoke with Irwin Simon, CEO of the new combined company. Check out the video below: Following the merger, Jefferies upgraded the rating for Tilray from Underperform to Buy, while raising the price target from $4.77 to $23. Jazz Pharmaceuticals (NASDAQ: JAZZ ) finalized its acquisition of GW Pharmaceuticals plc. (NASDAQ: GWPH ), the producer of the FDA‑approved prescription cannabidiol drug Epidiolex, for $7.2 billion or $6.7 billion net of GW Pharma's cash. Meanwhile, Ascend Wellness Holdings (CSE: AAWH) started trading on the Canadian Securities exchange following a raise of approximately $80 million through an initial public offering of roughly 10 million shares of its Class A common stock at $8 per share. Benzinga Cannabis’ content is now available in Spanish on El Planteo .
   Jazz Pharmaceuticals Closes On Acquisition Of GW Pharma, Adds CBD Drug Epidiolex To Portfolio  2021/05/06 14:16:29 Benzinga
The biopharmaceutical company Jazz Pharmaceuticals (NASDAQ: JAZZ ), has finalized the acquisition of the cannabinoid drug company GW Pharmaceuticals plc. (NASDAQ: GWPH ). The transaction, previously announced in February, was recently approved by GW Pharmaceuticals shareholders. The Jazz-GW Pharma Deal: Under the terms of the agreement, the Ireland-based company agreed to purchase the producer of the FDA‑approved prescription cannabidiol dryg Epidiolex for $7.2 billion or $6.7 billion net of GW Pharma's cash. Holders of GW ADSs, with each representing 12 GW ordinary shares, would obtain $220 for each GW ADS, including … Full story available on Benzinga.com
   The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data  2021/05/04 12:10:20 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV ) BioNTech SE – ADR (NASDAQ: BNTX ) (moving on momentum imparted by vaccine news flow) GT Biopharma Inc (NASDAQ: GTBP ) GW Pharmaceuticals PLC- ADR (NASDAQ: GWPH ) Lantheus Holdings Inc (NASDAQ: LNTH ) Orthopediatrics Corp (NASDAQ: KIDS ) Quest Diagnostics Incorporated (NYSE: DGX ) West Pharmaceutical Services, Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aptinyx Inc. (NASDAQ: APTX ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AVROBIO, Inc. (NASDAQ: AVRO ) (reacted to the need for conducting a registrational trial for its gene therapy candidate for Fabry disease) Aziyo Biologics, Inc. (NASDAQ: AZYO ) Celyad Oncology SA (NASDAQ: CYAD ) Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX ) Cyclerion Therapeutics, Inc. (NASDAQ: CYCN ) Decibel Therapeutics, Inc.
   No Reefer Madness Here: 5 Cannabis-Focused Stocks For The 420 Trader  2021/04/20 17:27:15 Benzinga
Investors looking to take their portfolios one toke over the line may wish to consider taking a look – preferably sober and without the narcotizing stimulation from the celebrated wacky weed – at the following quintet of cannabis industry-focused stocks. ETFMG Alternative Harvest ETF (NYSE: MJ ) Founded in 2014 and headquartered in Summit New Jersey, this is the largest cannabis-focused exchange-traded fund on the market and the first and only U.S.-listed ETF to target the global cannabis industry directly, via the Prime Alternative Harvest Index. The top holding in this ETF’s portfolio is the 10.35% share of Britain’s GW Pharmaceuticals plc (NASDAQ: GWPH ), followed by a 9.88% share of Canada’s Aphria Inc. (NASDAQ: APHA ) and a 7.01% share of Tilray Inc. (NASDAQ: TLRY ). On Dec. 4, 2020, this ETF reached the mark of $1 billion assets under management. MJ trades around at $20.18, which is between its 52-week high of $34.58 and its 52-week low of $10.12 See Also: Cannabis Insider | Benzinga’s Cannabis Trading For Cannabis Investors cbdMD (NYSE: YCBD ) Founded in 2015 and headquartered in Charlotte, North Carolina, this company offers a line of consumer hemp-based cannabidiol (CBD) products, including gummies, tinctures, vape oils, topicals, bath bombs and pet products for the U.S. market.
   Moore Kuehn Encourages GWPH, GNPK, PMBC, and SPFR Investors to Contact Law Firm  2021/03/25 10:42:00 Benzinga
NEW YORK, March 25, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 GWファ―マシュ―ティカルズ GWPH GW Pharmaceuticals Plc)

 twitter  (公式ツイッターやCEOツイッターなど)